| Lipids Management |
1 |
1 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.99 |
| Cholesteryl Ester Transfer Protein (CETP) Inhibitor |
0 |
0.98 |
| Cardiovascular Risk Management |
0 |
0.53 |
| Statins |
0 |
0.44 |
| PCSK9 |
0 |
0.14 |
| Blood |
0 |
0.12 |
| Genetics |
0 |
0.12 |
| Genomic Medicine |
0 |
0.11 |
| Increased Blood Pressure |
0 |
0.11 |
| Coronary Artery Disease (CAD) |
0 |
0.09 |
| Hypertension |
0 |
0.09 |
| LDL Cholesterol |
0 |
0.97 |
| Toxicology |
0 |
0.07 |
| Type 2 Diabetes Mellitus |
0 |
0.07 |
| Adverse Effects |
0 |
0.04 |
| Board Certification |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Drug Development |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Heart |
0 |
0.04 |
| Patient Safety |
0 |
0.04 |
| Triglycerides |
0 |
0.04 |